All-optical image processing has been viewed as a promising technique for its high computation speed and low power ...

A multi-disciplinary team of researchers linked atomic-scale features to efficient heat-to-electricity conversion, offering ...

Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...

SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...

SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...

The Student Affairs Mentoring Program and Leadership Experience (SAMPLE) is designed for undergraduate students who are interested in higher education and student affairs. Through this program, which ...

EMBED <iframe src="https://archive.org/embed/retro-sample-cds" width="560" height="384" frameborder="0" webkitallowfullscreen="true" mozallowfullscreen="true ...